Thrombocytopenia represents a common hematological abnormality during pregnancy, affecting up to 10% of pregnant women, ranging from the clinically benign to processes that can threaten both mother and fetus. 
While gestational thrombocytopenia accounts for the majority of cases, immune thrombocytopenic purpura (ITP) represents a less frequent but clinically significant condition due to potential maternal hemorrhagic complications, particularly during delivery. 
Among pathological causes, immune thrombocytopenia (ITP) consists relatively rare, occurring in fewer than 0.1% of pregnancies, yet it remains the most common cause of thrombocytopenia in the first trimester.
ITP is an autoimmune disorder characterized by IgG-mediated platelet destruction and impaired platelet production. Although many affected women are asymptomatic, severe thrombocytopenia may increase the risk of maternal bleeding, particularly during delivery and the postpartum period, making management essential. In recent years, significant advances have been made in the treatment of ITP, but management in pregnancy is further complicated by the potential impact on the fetus, as maternal antiplatelet antibodies may cross the placenta. 
Therefore, any proposed intervention must carefully balance maternal benefit against potential fetal risk. Given these complexities, optimal care requires close multidisciplinary collaboration among hematologists, obstetricians, and anesthesiologists to enhance diagnostic clarity, individualize treatment strategies, and ensure safe peripartum management for both mother and neonate.
Aim of our study consists presentation of pregnancy surveillance accompanied with ITP, in order to depict optimal maternal and fetal outcome.